Synaffix B.V., a Lonza (LZAGY) company, announced it has entered into a licensing agreement with Illumina (ILMN). The agreement grants Illumina access to Synaffix’s patented metal-free click chemistry technology. Synaffix’s patented metal-free click chemistry will be used in relation to certain Illumina next-generation sequencing products.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina releasing expanded version of TruSight Oncology portfolio
- Cantor sees six changes to Nasdaq 100 Index in December rebalance
- Nvidia initiated, Airbnb downgraded: Wall Street’s top analyst calls
- Illumina resumed with an Equal Weight at Morgan Stanley
- Illumina price target raised to $184 from $170 at Stephens